Abstract
Glioblastoma multiforme (GBM) is the most aggressive brain tumor that grows and spreads quickly. Its malignancy is also due to high resistance to conventional therapies, poor prognosis and high post-therapy recurrence rate with survival of only 1-2 years. Previous work by the group contributed to new proposals for molecular targets that offer an advantage in pre-sensitizing tumor cells an…